$TRAW
Traws Pharma, Inc.

2014 Q1 Form 10-K Financial Statement

#000104746914002718 Filed on March 20, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013 Q3
Revenue $447.0K $1.930M $1.116M
YoY Change -59.95% -34.99% -97.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.930M $4.400M $5.930M
YoY Change 47.16% 62.96% -33.52%
% of Gross Profit
Research & Development $14.25M $12.09M $15.29M
YoY Change 11.7% 14.28% -43.28%
% of Gross Profit
Depreciation & Amortization $141.0K $120.0K $120.0K
YoY Change 43.88% 33.33% 71.43%
% of Gross Profit
Operating Expenses $19.18M $16.49M $21.22M
YoY Change 19.12% 24.22% -40.87%
Operating Profit -$18.73M -$14.56M -$20.10M
YoY Change 25.0% 41.28% -390.56%
Interest Expense $20.00K $1.000K $1.000K
YoY Change 100.0% -99.99%
% of Operating Profit
Other Income/Expense, Net $1.000K -$126.0K $47.00K
YoY Change -99.21% -407.32% 67.86%
Pretax Income -$18.72M -$14.63M -$20.09M
YoY Change 26.1% 42.52% 1299.93%
Income Tax $0.00 $3.000K $432.0K
% Of Pretax Income
Net Earnings -$18.68M -$14.62M -$20.52M
YoY Change 25.83% 42.42% 1330.03%
Net Earnings / Revenue -4178.75% -757.25% -1838.8%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.868B -$1.462B -$2.052B
COMMON SHARES
Basic Shares Outstanding 21.64M shares 21.41M shares 21.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.60M $100.0M $116.6M
YoY Change 25.71%
Cash & Equivalents $54.62M $60.01M $76.61M
Short-Term Investments $30.00M $40.00M $40.00M
Other Short-Term Assets $520.0K $449.0K $395.0K
YoY Change -80.74% 130.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $89.02M $104.4M $121.9M
YoY Change 27.18% 25.39%
LONG-TERM ASSETS
Property, Plant & Equipment $557.0K $626.0K $652.0K
YoY Change -7.17% 35.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $12.00K $12.00K
YoY Change -88.0% 0.0%
Total Long-Term Assets $694.0K $763.0K $789.0K
YoY Change -13.25% 27.17%
TOTAL ASSETS
Total Short-Term Assets $89.02M $104.4M $121.9M
Total Long-Term Assets $694.0K $763.0K $789.0K
Total Assets $89.72M $105.2M $122.7M
YoY Change 26.72% 25.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.302M $3.710M $4.405M
YoY Change -21.38% -32.75%
Accrued Expenses $7.600M $5.500M $7.400M
YoY Change 35.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.56M $10.34M $14.83M
YoY Change -59.02% -59.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000K $6.000K $30.00K
YoY Change -99.98% -86.36%
Total Long-Term Liabilities $3.000K $6.000K $30.00K
YoY Change -99.98% -86.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.56M $10.34M $14.83M
Total Long-Term Liabilities $3.000K $6.000K $30.00K
Total Liabilities $25.35M $24.25M $28.89M
YoY Change -40.34% -40.62%
SHAREHOLDERS EQUITY
Retained Earnings -$249.6M -$230.9M -$216.3M
YoY Change 37.15%
Common Stock $313.5M $311.3M $310.1M
YoY Change 2998.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.91M $80.41M $93.83M
YoY Change
Total Liabilities & Shareholders Equity $89.72M $105.2M $122.7M
YoY Change 26.72% 25.4%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$18.68M -$14.62M -$20.52M
YoY Change 25.83% 42.42% 1330.03%
Depreciation, Depletion And Amortization $141.0K $120.0K $120.0K
YoY Change 43.88% 33.33% 71.43%
Cash From Operating Activities -$16.17M -$17.13M -$14.37M
YoY Change 15.91% -38.2% -134.54%
INVESTING ACTIVITIES
Capital Expenditures $72.00K -$90.00K -$50.00K
YoY Change -74.65% -40.0% -58.33%
Acquisitions
YoY Change
Other Investing Activities $10.00M $0.00 -$39.99M
YoY Change
Cash From Investing Activities $9.930M -$90.00K -$40.04M
YoY Change -3646.43% -40.0% 33266.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 850.0K 600.0K 79.85M
YoY Change 8400.0% -52.0% 24.47%
NET CHANGE
Cash From Operating Activities -16.17M -17.13M -14.37M
Cash From Investing Activities 9.930M -90.00K -40.04M
Cash From Financing Activities 850.0K 600.0K 79.85M
Net Change In Cash -5.390M -16.62M 25.44M
YoY Change -62.1% -37.57% -75.92%
FREE CASH FLOW
Cash From Operating Activities -$16.17M -$17.13M -$14.37M
Capital Expenditures $72.00K -$90.00K -$50.00K
Free Cash Flow -$16.24M -$17.04M -$14.32M
YoY Change 14.11% -38.19% -134.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Profit Loss
ProfitLoss
-12562000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
13164000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12573000 USD
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2000 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12562000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-12562000 USD
CY2013Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1032000 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13594000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.21
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2609495 shares
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3346000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12756000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
16102000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14986000 USD
CY2013Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
127000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14845000 USD
CY2013Q1 us-gaap Profit Loss
ProfitLoss
-14845000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-14845000 USD
CY2013Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1019000 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15864000 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.08
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2607406 shares
CY2012Q4 us-gaap Revenues
Revenues
2969000 USD
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2698000 USD
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10576000 USD
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
13274000 USD
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10305000 USD
CY2012Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10262000 USD
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2305315 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2174392 shares
CY2012Q4 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1010000 USD
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11272000 USD
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.89
CY2012Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000 USD
CY2012Q4 us-gaap Profit Loss
ProfitLoss
-10262000 USD
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-10262000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2220000 USD
CY2012Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
785000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-1435000 USD
CY2012Q3 us-gaap Profit Loss
ProfitLoss
-1435000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1435000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
8357000 USD
CY2012Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6919000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
35884000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26962000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8922000 USD
CY2012Q3 us-gaap Revenues
Revenues
42803000 USD
CY2012Q2 us-gaap Revenues
Revenues
220000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1627000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6776000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
8403000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8183000 USD
CY2012Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-999000 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
230000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7416000 USD
CY2012Q2 us-gaap Profit Loss
ProfitLoss
-7416000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-7416000 USD
CY2012Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
927000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8343000 USD
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.84
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2173549 shares
CY2012Q1 us-gaap Revenues
Revenues
198000 USD
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2460000 USD
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8448000 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
10908000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10710000 USD
CY2012Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
609000 USD
CY2012Q1 us-gaap Interest Expense
InterestExpense
21000 USD
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
541000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10799000 USD
CY2012Q1 us-gaap Profit Loss
ProfitLoss
-10799000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-10799000 USD
CY2012Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1231000 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12030000 USD
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.53
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2173553 shares
CY2013 ontx Treasury Note Discount Amortization
TreasuryNoteDiscountAmortization
-4000 USD
CY2013 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
500000 USD
CY2013 ontx Payment In Lieu Of Fractional Shares For Reverse Stock Split
PaymentInLieuOfFractionalSharesForReverseStockSplit
4000 USD
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
435000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2402000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1811000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1776000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1348000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
626000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463000 USD
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
446000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
319000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
316000 USD
CY2013 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>1. Nature of Business</b></font></p> <p style="FONT-FAMILY: times;"><font size="2"><b>The Company</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Onconova Therapeutics,&#160;Inc. (the "Company") was incorporated in the State of Delaware on December&#160;22, 1998 and commenced operations on January&#160;1, 1999. The Company's headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using its proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The Company believes that the drug candidates in its pipeline have the potential to be efficacious in a wide variety of cancers without causing harm to normal cells. The Company has three clinical-stage product candidates and six preclinical programs. To accelerate and broaden the development of rigosertib, the Company's most advanced product candidate, the Company entered into a collaboration and license agreement in 2012 with Baxter Healthcare&#160;SA ("Baxter"), a subsidiary of Baxter International&#160;Inc., to commercialize rigosertib in Europe. In 2011, the Company entered into a collaboration and license agreement with SymBio Pharmaceuticals Limited ("SymBio") to commercialize rigosertib in Japan and Korea. The Company has retained development and commercialization rights to rigosertib in the rest of the world, including the United States. During 2012, Onconova Europe&#160;GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe. In April 2013, GBO,&#160;LLC, a Delaware limited liability company, ("GBO") was formed pursuant to a collaboration agreement with GVK Biosciences Private Limited, a private limited company located in India, ("GVK BIO") to collaborate and develop two new clinical programs using the Company's technology platform.</font></p> <p style="FONT-FAMILY: times;"><font size="2"><b>Liquidity</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has incurred recurring operating losses since inception. For the year ended December&#160;31, 2013, the Company incurred a net loss of $62,556,000 and as of December&#160;31, 2013, the Company had generated an accumulated deficit of $230,896,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances and the development of its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company raised significant capital through the issuance of its redeemable convertible preferred stock, par value $0.01 per share, in ten series denominated as Series&#160;A through Series&#160;J ("Series&#160;A Preferred Stock" through "Series&#160;J Preferred Stock," respectively, and collectively the "Preferred Stock"). See Note&#160;10.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On July&#160;30, 2013, the Company completed its initial public offering (the "IPO") of 5,941,667 shares of the Company's common stock, par value $0.01 per share ("Common Stock"), at a price of $15.00 per share, including 775,000 shares of Common Stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. The Company received net proceeds of $79,811,000 from the sale, net of underwriting discounts and commissions and other estimated offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect. As a result of the conversion, as of July&#160;30, 2013, the Company had no shares of Preferred Stock outstanding. See Note&#160;10.</font></p> </div>
CY2013Q4 ontx Number Of Clinical Stage Product Candidates
NumberOfClinicalStageProductCandidates
3 item
CY2013Q4 ontx Number Of Preclinical Programs
NumberOfPreclinicalPrograms
6 item
CY2013Q2 ontx Number Of Clinical Programs Developed
NumberOfClinicalProgramsDeveloped
2 item
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-62543000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230896000 USD
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2013 ontx Number Of Series Denominations Of Preferred Stock
NumberOfSeriesDenominationsOfPreferredStock
10 item
CY2013 us-gaap Profit Loss
ProfitLoss
-62556000 USD
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10594227 shares
CY2012 us-gaap Profit Loss
ProfitLoss
-29912000 USD
CY2011 us-gaap Profit Loss
ProfitLoss
-26294000 USD
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2320000 USD
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3953000 USD
CY2011 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4020000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64863000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33865000 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30314000 USD
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2206888 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2137403 shares
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.12
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.35
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.18
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4348962 shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15406871 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11028853 shares
CY2013Q4 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
2242000 USD
CY2012Q4 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1429000 USD
CY2013Q4 ontx Prepaid Manufacturing
PrepaidManufacturing
1051000 USD
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
195000 USD
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
645000 USD
CY2012Q4 us-gaap Prepaid Insurance
PrepaidInsurance
101000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4387000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1725000 USD
CY2013Q4 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4625000 USD
CY2012Q4 ontx Deferred Tax Assets Tax Non Qualified Stock Options
DeferredTaxAssetsTaxNonQualifiedStockOptions
1057000 USD
CY2012Q4 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3521000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
509000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
247000 USD
CY2013Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
302000 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
384000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
157000 USD
CY2013Q4 ontx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
5820000 USD
CY2012Q4 ontx Accrued Expenses And Other Current Liabilities Current
AccruedExpensesAndOtherCurrentLiabilitiesCurrent
3925000 USD
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
79811000 USD
CY2013Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.75 pure
CY2013Q3 ontx Designated Public Offering Amended Threshold Gross Proceeds Minimum
DesignatedPublicOfferingAmendedThresholdGrossProceedsMinimum
25000000 USD
CY2013Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
35085000 USD
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47364000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
35921000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
35223000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
13868000 USD
CY2013Q4 ontx Deferred Tax Assets Tax Non Qualified Stock Options
DeferredTaxAssetsTaxNonQualifiedStockOptions
3988000 USD
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5938000 USD
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4246000 USD
CY2013Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
6000 USD
CY2012Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
6000 USD
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
586000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
40000 USD
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
199000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
159000 USD
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
93304000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55297000 USD
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
93304000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55297000 USD
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.083 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.251 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.344 pure
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.018 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.185 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.516 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.612 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.291 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001 pure
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006 pure
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6107831 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4107831 shares
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8015000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13844000 USD
CY2013Q4 ontx Employee Service Share Based Compensation Nonvested Liability Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedLiabilityAwardsTotalCompensationCostNotYetRecognized
1875000 USD
CY2013 ontx Employee Service Share Based Compensation Nonvested Liability Awards Total Compensation Cost Not Yet Recognized Period For Recognition
EmployeeServiceShareBasedCompensationNonvestedLiabilityAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition
P2Y3M25D
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3597000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M24D
CY2013Q4 us-gaap Minority Interest
MinorityInterest
487000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80900000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-158306000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-13000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-62542000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29912000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-26294000 USD
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
4344365 shares
CY2013 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y10M28D
CY2013Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2347744 shares
CY2013 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
309000 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
233000 USD
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
186000 USD
CY2013Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
0 USD
CY2013Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2012Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2013Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2012Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2013Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2012Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2013Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
CY2012Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
24253000 USD
CY2011 ontx Research And Development Revenue
ResearchAndDevelopmentRevenue
1260000 USD
CY2013Q2 ontx Adjustments To Additional Paid In Capital Share Based Compensation Reclassification Adjustment Of Stock Option Liability
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationAdjustmentOfStockOptionLiability
14482000 USD
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, other comprehensive income and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals, warrant liability, and allocation of consideration to multiple element collaborative arrangements. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></p> <p style="FONT-FAMILY: times;"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to completion of its IPO on July&#160;30, 2013, the Company utilized estimates and assumptions in determining the fair value of its Common Stock. The Company granted stock options at exercise prices not less than the fair value of its Common Stock as determined by the board of directors, with input from management. Management used the assistance of a third-party valuation firm in estimating the fair value of the Common Stock. The board of directors determined the estimated fair value of the Common Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of Preferred Stock.</font></p> </div>
CY2012Q4 us-gaap Liabilities
Liabilities
40843000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
201315000 USD
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 item
CY2013Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0 USD
CY2013Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Liability
FairValueDisclosureOffbalanceSheetRisksAmountLiability
0 USD
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000 USD
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
215000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
26000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
311093000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10021000 USD
CY2012 ontx Research And Development Revenue
ResearchAndDevelopmentRevenue
197000 USD
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30145155 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2606484 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2606484 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21467482 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21467482 shares
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000 USD
CY2013Q3 ontx Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 item
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
245000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
39000 USD
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
284000 USD
CY2013 ontx Defined Contribution Plan Minimum Age Of Employees
DefinedContributionPlanMinimumAgeOfEmployees
P21Y
CY2013 ontx Defined Contribution Plan Employer Matching Contribution For Every Dollar Of First Specified Percentage Of Payroll That Employees Invest
DefinedContributionPlanEmployerMatchingContributionForEveryDollarOfFirstSpecifiedPercentageOfPayrollThatEmployeesInvest
0.50 USD
CY2013 ontx Defined Contribution Plan First Specified Percentage Of Payroll That Employees Invest
DefinedContributionPlanFirstSpecifiedPercentageOfPayrollThatEmployeesInvest
0.06 pure
CY2013 ontx Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P4Y
CY2013 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.25 pure
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
289000 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
159000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
131000 USD
CY2013 ontx Defined Contribution Plan Minimum Working Hours Per Year
DefinedContributionPlanMinimumWorkingHoursPerYear
PT1000H
CY2013 dei Entity Registrant Name
EntityRegistrantName
Onconova Therapeutics, Inc.
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001130598
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2013Q2 dei Entity Public Float
EntityPublicFloat
107300000 USD
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21638029 shares
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60009000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81527000 USD
CY2013Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
39994000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
104390000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
83252000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000 USD
CY2013Q4 us-gaap Assets
Assets
105153000 USD
CY2012Q4 us-gaap Assets
Assets
83852000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3710000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5517000 USD
CY2013Q4 ontx Warrant Liability Current
WarrantLiabilityCurrent
20000 USD
CY2012Q4 ontx Warrant Liability Current
WarrantLiabilityCurrent
62000 USD
CY2012Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
11967000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
788000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3907000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10338000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25378000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13909000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15421000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168353000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
80413000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-158306000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105153000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83852000 USD
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2012Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
18548253 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
16912199 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
16912199 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2013 us-gaap Revenues
Revenues
4753000 USD
CY2012 us-gaap Revenues
Revenues
46190000 USD
CY2011 us-gaap Revenues
Revenues
1487000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16793000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15707000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6436000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50182000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52762000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22624000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
66975000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
68469000 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
29060000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-62222000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-22279000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-27573000 USD
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-42000 USD
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-367000 USD
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1287000 USD
CY2013 us-gaap Interest Expense
InterestExpense
4000 USD
CY2012 us-gaap Interest Expense
InterestExpense
8608000 USD
CY2011 us-gaap Interest Expense
InterestExpense
19000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
608000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-62121000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-29912000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-26294000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
435000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-29912000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-26294000 USD
CY2013 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62555000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29912000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26294000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-138419000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
612000 USD
CY2011 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-4020000 USD
CY2013Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4694000 USD
CY2012 ontx Adjustments To Additional Paid In Capital Share Based Compensation Settlement Of Option Liability
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSettlementOfOptionLiability
-2835000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
8176000 USD
CY2012 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-3953000 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5462000 USD
CY2013 ontx Adjustments To Additional Paid In Capital Share Based Compensation Reclassification Adjustment Of Stock Option Liability
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationAdjustmentOfStockOptionLiability
14482000 USD
CY2013 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
-203631000 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
79811000 USD
CY2013 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-2320000 USD
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
15000 USD
CY2011 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21000 USD
CY2012 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8176000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
8015000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
13844000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
6000 USD
CY2012 ontx Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-78000 USD
CY2011 ontx Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-1730000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2662000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1098000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-253000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
15000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1807000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-97000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2230000 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1894000 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2573000 USD
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1123000 USD
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-37000 USD
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-41000 USD
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
58000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4631000 USD
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
8155000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7673000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-61384000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1633000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14171000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
609000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
279000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
256000 USD
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39990000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40599000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-279000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-241000 USD
CY2013 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
79811000 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
157000 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
165000 USD
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
154000 USD
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2167000 USD
CY2011 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1918000 USD
CY2012 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25824000 USD
CY2011 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
620000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
80464000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
77460000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9785000 USD
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1000 USD
CY2013 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-21518000 USD
CY2012 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
78814000 USD
CY2011 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4627000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7340000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2713000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20104000 USD
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
31000 USD
CY2012 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000 USD
CY2011 ontx Proceeds From Security Deposits
ProceedsFromSecurityDeposits
15000 USD
CY2012 ontx Proceeds From Stockholder In Connection With Settlement Of Stock Option Exercises
ProceedsFromStockholderInConnectionWithSettlementOfStockOptionExercises
3943000 USD
CY2012 ontx Payments For Settlements Of Stock Options
PaymentsForSettlementsOfStockOptions
2835000 USD
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
917000 USD
CY2011 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
792000 USD
CY2013Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2012 ontx Adjustments To Additional Paid In Capital Proceeds From Stockholder In Connection With Settlement Of Stock Option Exercises
AdjustmentsToAdditionalPaidInCapitalProceedsFromStockholderInConnectionWithSettlementOfStockOptionExercises
3943000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-62154000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29912000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
33000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
1000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
2000 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20089000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
432000 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-20521000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-20521000 USD
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
140000 USD
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
285000 USD
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
10000 USD
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
435000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8718000 USD
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
38007000 USD
CY2013 ontx Defined Contribution Plan Employer Matching Contribution For Every Dollar Of First Specified Percentage Of Payroll That Employees Invest For Period Beginning After Current Fiscal Year
DefinedContributionPlanEmployerMatchingContributionForEveryDollarOfFirstSpecifiedPercentageOfPayrollThatEmployeesInvestForPeriodBeginningAfterCurrentFiscalYear
0.60 USD
CY2013 ontx Minority Interest Increase Decrease
MinorityInterestIncreaseDecrease
500000 USD
CY2013Q4 us-gaap Revenues
Revenues
1930000 USD
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4403000 USD
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12086000 USD
CY2013Q4 us-gaap Operating Expenses
OperatingExpenses
16489000 USD
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14559000 USD
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-61000 USD
CY2013Q4 us-gaap Interest Expense
InterestExpense
1000 USD
CY2013Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126000 USD
CY2013Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14625000 USD
CY2013Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 USD
CY2013Q4 us-gaap Profit Loss
ProfitLoss
-14628000 USD
CY2013Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13000 USD
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-14615000 USD
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14615000 USD
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21419208 shares
CY2013Q3 us-gaap Revenues
Revenues
1116000 USD
CY2013Q2 us-gaap Revenues
Revenues
591000 USD
CY2013Q1 us-gaap Revenues
Revenues
1116000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5927000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15293000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
21220000 USD
CY2013Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
269000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20790000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15480416 shares
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3117000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10047000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-26294000 USD
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.056 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.221 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000 pure
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013 ontx Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.038 pure
CY2012 ontx Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
0.000 pure
CY2011 ontx Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.051 pure
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-108717000 USD

Files In Submission

Name View Source Status
0001047469-14-002718-index-headers.html Edgar Link pending
0001047469-14-002718-index.html Edgar Link pending
0001047469-14-002718.txt Edgar Link pending
0001047469-14-002718-xbrl.zip Edgar Link pending
a2219098z10-k.htm Edgar Link pending
a2219098zex-21_1.htm Edgar Link pending
a2219098zex-23_1.htm Edgar Link pending
a2219098zex-23_2.htm Edgar Link pending
a2219098zex-31_1.htm Edgar Link pending
a2219098zex-31_2.htm Edgar Link pending
a2219098zex-32_1.htm Edgar Link pending
a2219098zex-32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g268054.jpg Edgar Link pending
g527675.jpg Edgar Link pending
g944849.jpg Edgar Link pending
ontx-20131231.xml Edgar Link completed
ontx-20131231.xsd Edgar Link pending
ontx-20131231_cal.xml Edgar Link unprocessable
ontx-20131231_def.xml Edgar Link unprocessable
ontx-20131231_lab.xml Edgar Link unprocessable
ontx-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending